Corbus Pharmaceuticals Holdings, Inc. Share-based Payment Arrangement, Expense
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Share-based Payment Arrangement, Expense of $1.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-06
- Corbus Pharmaceuticals Holdings, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $1.81M, a 15.55% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $1.92M, a 11.79% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $6.28M, a 2.32% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $1.58K, a 29.47% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. share-based payment arrangement, expense for fiscal 2025 was $6.29M, a 2.33% increase from fiscal 2024.
- Corbus Pharmaceuticals Holdings, Inc. share-based payment arrangement, expense for fiscal 2024 was $6.14M, a 77.09% increase from fiscal 2023.
- Corbus Pharmaceuticals Holdings, Inc. share-based payment arrangement, expense for fiscal 2023 was $3.47M, a 39.33% decline from fiscal 2022.
- Corbus Pharmaceuticals Holdings, Inc. share-based payment arrangement, expense for fiscal 2022 was $5.72M, a 39.67% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.81M 10-Q · filed 2026-08-06 | $3.72M 10-Q · filed 2026-08-06 | $10.01M derived: sum of 3 quarters · filed 2026-08-06 | $10.01M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $1.92M 10-Q · filed 2026-05-12 | $8.20M derived: sum of 2 quarters · filed 2026-05-12 | $8.20M derived: sum of 3 quarters · filed 2026-05-12 | $9.76M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $6.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $6.28M derived: sum of 2 quarters · filed 2026-03-09 | $7.85M derived: sum of 3 quarters · filed 2026-08-06 | $6.29M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $1.58K 10-Q · filed 2025-11-12 | $1.56M derived: sum of 2 quarters · filed 2026-08-06 | $4.86K 10-Q · filed 2025-11-12 | $9.42M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $1.56M 10-Q · filed 2026-08-06 | $1.56K 10-Q · filed 2025-08-05 | $3.28M 10-Q · filed 2026-08-06 | $3.28K 10-Q · filed 2025-08-05 | $9.42M derived: sum of 3 quarters · filed 2026-08-06 | $9.42M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $1.71M 10-Q · filed 2026-05-12 | $1.71K 10-Q · filed 2025-05-06 | $7.85M derived: sum of 2 quarters · filed 2026-05-12 | $7.86M derived: sum of 3 quarters · filed 2026-05-12 | $7.86M derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2024-12-31 | $6.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $6.14M derived: sum of 2 quarters · filed 2026-03-09 | $6.14M derived: sum of 3 quarters · filed 2026-03-09 | $6.14M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $2.24K 10-Q · filed 2025-11-12 | $2.24M 10-Q · filed 2024-11-07 | $3.53K derived: sum of 2 quarters · filed 2025-11-12 | $4.51K 10-Q · filed 2025-11-12 | $4.51M 10-Q · filed 2024-11-07 | $803.51K derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $1.29K 10-Q · filed 2025-08-05 | $1.29M 10-Q · filed 2024-08-06 | $2.27K 10-Q · filed 2025-08-05 | $2.27M 10-Q · filed 2024-08-06 | $801.27K derived: sum of 3 quarters · filed 2025-08-05 | $1.62M derived: sum of 4 quarters · filed 2025-08-05 | ||
| 2024-03-31 | $982.00 10-Q · filed 2025-05-06 | $982.02K 10-Q · filed 2024-05-07 | $799.98K derived: sum of 2 quarters · filed 2025-05-06 | $1.62M derived: sum of 3 quarters · filed 2025-05-06 | $2.44M derived: sum of 4 quarters · filed 2025-05-06 | |||
| 2023-12-31 | $799.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $1.62M derived: sum of 2 quarters · filed 2025-03-11 | $2.44M derived: sum of 3 quarters · filed 2025-03-11 | $3.47M 10-K · filed 2025-03-11 | $3.47M 10-K · filed 2024-03-12 | |||
| 2023-09-30 | $821.00K 10-Q · filed 2024-11-07 | $821.22K 10-Q · filed 2023-11-07 | $1.64M derived: sum of 2 quarters · filed 2024-11-07 | $2.67M 10-Q · filed 2024-11-07 | $2.67M 10-Q · filed 2023-11-07 | $3.94M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $823.00K 10-Q · filed 2024-08-06 | $823.38K 10-Q · filed 2023-08-08 | $1.85M 10-Q · filed 2024-08-06 | $1.85M 10-Q · filed 2023-08-08 | $3.12M derived: sum of 3 quarters · filed 2024-08-06 | $4.46M derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | $1.03M 10-Q · filed 2024-05-07 | $2.30M derived: sum of 2 quarters · filed 2024-05-07 | $3.64M derived: sum of 3 quarters · filed 2024-05-07 | $5.15M derived: sum of 4 quarters · filed 2024-05-07 | ||||
| 2022-12-31 | $1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $2.61M derived: sum of 2 quarters · filed 2024-03-12 | $4.13M derived: sum of 3 quarters · filed 2024-03-12 | $5.72M 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | $1.35M 10-Q · filed 2023-11-07 | $2.86M derived: sum of 2 quarters · filed 2023-11-07 | $4.45M 10-Q · filed 2023-11-07 | $6.24M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | $1.51M 10-Q · filed 2023-08-08 | $3.10M 10-Q · filed 2023-08-08 | $4.90M derived: sum of 3 quarters · filed 2023-08-08 | $7.50M derived: sum of 4 quarters · filed 2023-08-08 | ||||
| 2022-03-31 | $1.59M 10-Q · filed 2023-05-09 | $3.39M derived: sum of 2 quarters · filed 2023-05-09 | $5.98M derived: sum of 3 quarters · filed 2023-05-09 | $8.49M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | $1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $4.39M derived: sum of 2 quarters · filed 2023-03-07 | $6.90M derived: sum of 3 quarters · filed 2023-03-07 | $9.48M 10-K · filed 2023-03-07 | ||||
| 2021-09-30 | $2.60M 10-Q · filed 2022-11-08 | $5.11M derived: sum of 2 quarters · filed 2022-11-08 | $7.69M 10-Q · filed 2022-11-08 | $10.03M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | $2.51M 10-Q · filed 2022-08-09 | $5.09M 10-Q · filed 2022-08-09 | $7.43M derived: sum of 3 quarters · filed 2022-08-09 | $11.06M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | $2.58M 10-Q · filed 2022-05-10 | $4.92M derived: sum of 2 quarters · filed 2022-05-10 | $8.55M derived: sum of 3 quarters · filed 2022-05-10 | $11.90M derived: sum of 4 quarters · filed 2022-05-10 | ||||
| 2020-12-31 | $2.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $5.97M derived: sum of 2 quarters · filed 2022-03-08 | $9.32M derived: sum of 3 quarters · filed 2022-03-08 | $12.46M 10-K · filed 2022-03-08 | ||||
| 2020-09-30 | $3.63M 10-Q · filed 2021-11-12 | $6.98M derived: sum of 2 quarters · filed 2021-11-12 | $10.12M 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | $3.35M 10-Q · filed 2021-08-12 | $6.49M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $3.14M 10-Q · filed 2021-05-13 | |||||||
| 2017-03-31 | $171.00K 10-Q · filed 2018-05-10 | |||||||
| 2016-12-31 | $222.00K 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |